Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
172
-
Total 13F shares, excl. options
-
18.8M
-
Shares change
-
-713K
-
Total reported value, excl. options
-
$1.4B
-
Value change
-
-$51.4M
-
Put/Call ratio
-
7.93
-
Number of buys
-
100
-
Number of sells
-
-56
-
Price
-
$74.78
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2021
191 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q4 2021.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 172 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.8M shares
of 27.8M outstanding shares and own 67.63% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.47M shares), VANGUARD GROUP INC (1.63M shares), FARALLON CAPITAL MANAGEMENT LLC (1.57M shares), STATE STREET CORP (1.13M shares), ARMISTICE CAPITAL, LLC (1.06M shares), NORTHERN TRUST CORP (1.01M shares), FIRST MANHATTAN CO (970K shares), RENAISSANCE TECHNOLOGIES LLC (714K shares), DIMENSIONAL FUND ADVISORS LP (602K shares), and Krensavage Asset Management, LLC (564K shares).
This table shows the top 172 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.